Scitop Bio-tech - Public Comps and Valuation Multiples

Scitop Bio-tech Overview

About Scitop Bio-tech

Beijing Scitop Bio-tech Co Ltd is engaged in production and sales of compound food additives, edible probiotic products and animal and plant micro-ecological preparations. The company engages in provision of biotechnology services, consulting, development, transfer; development and sale of stereotyped packaged food additives, compound food additives. Its products include Probio-M8 and Probio-M9.

Founded

2003

HQ

Employees

402

Website

scitop.cn

Sectors

Nutraceuticals & Cosmeceuticals
BioTech

Financials

Last FY Revenue $43.3M

Last FY EBITDA $19.3M

EV

$645M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Scitop Bio-tech Financials

See Scitop Bio-tech valuation multiples based on analyst estimates

Scitop Bio-tech P&L

In the most recent fiscal year, Scitop Bio-tech reported revenue of $43.3M and EBITDA of $19.3M.

Scitop Bio-tech expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Scitop Bio-tech valuation multiples based on analyst estimates

	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	XXX	$43.3M	XXX	XXX	XXX
Gross Profit	XXX	$25.2M	XXX	XXX	XXX
Gross Margin	XXX	58%	XXX	XXX	XXX
EBITDA	XXX	$19.3M	XXX	XXX	XXX
EBITDA Margin	XXX	45%	XXX	XXX	XXX
EBIT	XXX	$10.8M	XXX	XXX	XXX
EBIT Margin	XXX	25%	XXX	XXX	XXX
Net Profit	XXX	$13.5M	XXX	XXX	XXX
Net Margin	XXX	31%	XXX	XXX	XXX
Net Debt	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Scitop Bio-tech including revenue, profitability, and margin analysis across different time periods. In the most recent fiscal year, Scitop Bio-tech achieved $43.3M in revenue and $19.3M in EBITDA.
Financial Metric	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	Analyst estimates available to subscribers	$43.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	Analyst estimates available to subscribers	$25.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	Analyst estimates available to subscribers	58.3% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	Analyst estimates available to subscribers	$19.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	Analyst estimates available to subscribers	44.7% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	Analyst estimates available to subscribers	$10.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	Analyst estimates available to subscribers	25.0% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	Analyst estimates available to subscribers	$13.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	Analyst estimates available to subscribers	31.2% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Scitop Bio-tech

This financial data table provides comprehensive performance metrics for Scitop Bio-tech, a company based in China. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Fiscal Year Performance

In the most recent fiscal year, Scitop Bio-tech reported $43.3M in total revenue.
Fiscal year EBITDA was $19.3M.
The company maintained a gross profit margin of 58.3% in the most recent fiscal year.
EBITDA margin for the fiscal year was 44.7%.
Net profit margin reached 31.2% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Scitop Bio-tech. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Scitop Bio-tech Stock Performance

Scitop Bio-tech has current market cap of CNY 4.7B (or $673M), and EV of CNY 4.5B (or $645M).

Market Cap Evolution

Scitop Bio-tech Stock Data

As of January 16, 2026, Scitop Bio-tech's stock price is CNY 18 (or $3).

See Scitop Bio-tech trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$645M	$673M	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Scitop Bio-tech Valuation Multiples

Scitop Bio-tech's trades at 14.9x EV/Revenue multiple, and 33.4x EV/EBITDA.

See valuation multiples for Scitop Bio-tech and 15K+ public comps

Scitop Bio-tech Financial Valuation Multiples

As of January 16, 2026, Scitop Bio-tech has market cap of $673M and EV of $645M.

Equity research analysts estimate Scitop Bio-tech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Scitop Bio-tech's P/E ratio is not available.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$673M	XXX	$673M	XXX	XXX	XXX
EV (current)	$645M	XXX	$645M	XXX	XXX	XXX
EV/Revenue	n/a	XXX	14.9x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	33.4x	XXX	XXX	XXX
EV/EBIT	n/a	XXX	59.7x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	n/a	XXX	49.9x	XXX	XXX	XXX
EV/FCF	n/a	XXX	-65.1x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Scitop Bio-tech Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Scitop Bio-tech Margins & Growth Rates

Scitop Bio-tech's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $36K for the same period.

Scitop Bio-tech's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Scitop Bio-tech's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Scitop Bio-tech and other 15K+ public comps

Scitop Bio-tech Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$36K	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	8%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	12%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	33%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial